Edition:
India

Anavex Life Sciences Corp (AVXL.OQ)

AVXL.OQ on NASDAQ Stock Exchange Capital Market

4.11USD
10:44pm IST
Change (% chg)

$-0.44 (-9.67%)
Prev Close
$4.55
Open
$5.00
Day's High
$5.05
Day's Low
$3.74
Volume
496,971
Avg. Vol
174,967
52-wk High
$6.30
52-wk Low
$2.21

Latest Key Developments (Source: Significant Developments)

Anavex Life Sciences Q3 Loss Per Share $0.11
4:30pm IST 

Aug 6 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q3 LOSS PER SHARE $0.11.Q3 EARNINGS PER SHARE ESTIMATE $-0.14 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS OF $27.6 MILLION AT JUNE 30.  Full Article

Anavex Life Sciences Q2 Loss Per Share $0.12
Thursday, 7 May 2020 

May 7 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q2 LOSS PER SHARE $0.12.Q2 EARNINGS PER SHARE ESTIMATE $-0.16 -- REFINITIV IBES DATA.  Full Article

Anavex Life Sciences Corp Files Prospectus Supplement Related To Issuance, Sale Of Up To $30.3 Million In Common Shares To Lincoln Park Capital Fund, Llc
Friday, 1 May 2020 

May 1 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES CORP FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE, SALE OF UP TO $30.3 MILLION IN COMMON SHARES TO LINCOLN PARK CAPITAL FUND, LLC.  Full Article

Anavex Life Sciences Corp - May Offer And Sell Shares Of Common Stock Having Offering Price Of Up To $50 Million From Time To Time
Friday, 1 May 2020 

May 1 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES CORP - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $50 MILLION FROM TIME TO TIME - SEC FILING.  Full Article

Anavex Life Sciences Q1 Loss Per Share $0.12
Thursday, 6 Feb 2020 

Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL STUDY UPDATES.Q1 LOSS PER SHARE $0.12.  Full Article

Anavex Life Sciences -Fast Track Designation Granted By FDA For Rett Syndrome Treatment
Monday, 3 Feb 2020 

Feb 3 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES ANNOUNCES FAST TRACK DESIGNATION GRANTED BY U.S. FDA FOR ANAVEX®2-73 (BLARCAMESINE) CLINICAL DEVELOPMENT PROGRAM FOR THE TREATMENT OF RETT SYNDROME.  Full Article

Anavex Life Sciences Q1 Loss Per Share $0.16
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES REPORTS FISCAL 2019 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL STUDY UPDATES.Q1 LOSS PER SHARE $0.16.CASH AND EQUIVALENTS OF $20.7 MILLION AT DECEMBER 31, 2018, COMPARED TO $22.9 MILLION AT SEPTEMBER 30, 2018..  Full Article

BRIEF-Anavex Life Sciences Announces First Participant Enrolled In Phase 1 Study Of Anavex 3-71

* ANAVEX LIFE SCIENCES ANNOUNCES FIRST PARTICIPANT ENROLLED IN PHASE 1 STUDY OF ANAVEX®3-71 (AF710B) Source text for Eikon: Further company coverage: